Emplastrum, a new device for treating skin conditions from home

EmPlastrum represents a significant advancement in the treatment of chronic skin conditions such as eczema, vitiligo, and psoriasis. Traditionally, managing these conditions requires frequent visits to hospitals for phototherapy, a process that can be both inconvenient and costly.

The EmPlastrum device aims to revolutionize this approach by bringing advanced narrowband UVB light therapy directly to patients' homes. With a press of a button, users can apply a precise dose of UVB light specifically to the affected areas of their skin, rather than exposing the entire body to light. This precise targeting ensures that only the problematic skin areas receive the treatment, minimizing the risk of damaging healthy skin and enhancing the overall effectiveness of the therapy.

Designed for ease of use, EmPlastrum is a wearable device that adheres to the skin, allowing patients to continue their daily activities while undergoing treatment. The device is paired with a mobile app, which enables users to track their progress and receive ongoing support from their healthcare provider, ensuring personalized and continuous care. Users are always connected to their EmPlastrum physician, who helps coach and support them throughout their treatment journey. This implies that healthcare professionals are involved in monitoring and guiding the use of the device to ensure effective and personalized care. This solution thus reduces the need for frequent hospital visits, offering a more convenient, cost-effective, and accessible way to manage chronic skin conditions.

Regulatory Information: Clinical trials were conducted in 2022, prior to delivering the first and second batches of the device, which are now available. It is important to note that while EmPlastrum holds a CE mark, indicating compliance with European health, safety, and environmental protection standards, it does not currently have FDA certification.

For more information:
https://emplastrum.tech/